# The metabolic score for visceral fat and risk of peripheral arterial disease in hypertension patients: a prospective cohort study

**Authors:** Shiping Li, Congcong Yan, Meihui Wu, Tao Wang, Lingjuan Zhu, Chao Yu, Weifang Zhang, Wei Zhou, Huihui Bao, Xiaoshu Cheng

PMC · DOI: 10.3389/fendo.2026.1764481 · Frontiers in Endocrinology · 2026-02-05

## TL;DR

This study found that a higher metabolic score for visceral fat increases the risk of peripheral artery disease in hypertensive patients, especially in non-smokers.

## Contribution

The study reveals a saturation effect of the METS-VF score on PAD risk in hypertensive patients.

## Key findings

- Each 1-unit increase in METS-VF raised the risk of PAD by 21.0% in fully adjusted models.
- A saturation effect was observed at METS-VF of 8.63, with no significant risk increase beyond this point.
- The association between METS-VF and PAD was stronger in non-smokers than in smokers.

## Abstract

The Metabolic Score for Visceral Fat (METS - VF), a novel metric for evaluating visceral adipose tissue, has been demonstrated to exhibit a significant correlation with an elevated cardiovascular risk. Nevertheless, its relationship with peripheral artery disease (PAD) remains ambiguous. Consequently, the present study aimed to explore the association between METS-VF and PAD.

This prospective study was based on a Chinese H-type hypertension cohort, comprising 6,452 patients. The association between METS-VF and PAD was evaluated using the Cox proportional hazards regression analysis and the method of restricted cubic splines (RCS). During an median follow-up time of 3.9 years, 266 PAD events occurred. The mean age of all participants was 63.20 ± 8.38 years. In the fully adjusted model, each 1-unit increase of METS-VF raised the risk of PAD by 21.0% (HR = 1.21, 95%CI: 1.07, 1.37). There was a saturation effect of METS-VF with an inflection point of 8.63 on PAD. For METS-VF < 8.63, each unit increase was associated with a 69.0% higher risk of PAD (HR=1.69, 95%CI: 1.32–2.16), while for METS-VF ≥8.63, there was no significant association between them (HR=0.93, 95%CI: 0.73–1.19) (P for log-likelihood ratio test= 0.002). Subgroup analysis further showed a significant interaction between METS-VF and current smoking status (P for interaction<0.05), with a stronger association observed in non-smokers.

METS-VF exhibited a saturation effect on PAD in hypertensive adults in China. Increased METS-VF was positively associated with a higher risk of PAD among hypertensive adults with METS-VF < 8.63, and this association was more pronounced in non-smokers.

## Linked entities

- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}
- **Diseases:** Diabetes (MESH:D003920), MTES-VF (MESH:C537182), non-alcoholic fatty liver disease (MESH:D065626), psychiatric (MESH:D001523), Chronic Kidney Disease (MESH:D051436), inflammation (MESH:D007249), CHD (MESH:D003327), atherosclerotic dyslipidemia (MESH:D050171), pain (MESH:D010146), neurological dysfunction (MESH:D009461), visceral adiposity (MESH:D007418), intermittent claudication (MESH:D007383), obesity (MESH:D009765), stroke (MESH:D020521), atrial fibrillation (MESH:D001281), cardiovascular disease (MESH:D002318), Insulin resistance (MESH:D007333), carotid atherosclerosis (MESH:D002340), cardiorenal metabolic syndrome (MESH:D059347), atherogenic (MESH:D050197), hyperinsulinemia (MESH:D006946), H-type hypertension (MESH:D006973), gangrene (MESH:D005734), heart failure (MESH:D006333), PAD (MESH:D058729), coronary artery calcification (MESH:D003324)
- **Chemicals:** UA (MESH:D014527), TG (MESH:D014280), cholesterol (MESH:D002784), free fatty acids (MESH:D005230), Hcy (MESH:D006710), Lipoprotein-lowering drugs (-), alcohol (MESH:D000438), glucose (MESH:D005947), lipid (MESH:D008055)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12916417/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12916417/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC12916417/full.md

---
Source: https://tomesphere.com/paper/PMC12916417